Immersive Virtual Reality for Stroke Motor Rehabilitation
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03094650 |
Recruitment Status :
Completed
First Posted : March 29, 2017
Last Update Posted : March 29, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Chronic Stroke Motor Disorders | Device: MindMotion PRO | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 10 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Primary Purpose: | Treatment |
Official Title: | The Use of Immersive Virtual Reality for Upper Limb Neurorehabilitation in Stroke Survivors |
Actual Study Start Date : | February 2015 |
Actual Primary Completion Date : | October 2015 |
Actual Study Completion Date : | November 2015 |

Arm | Intervention/treatment |
---|---|
Experimental: MindMotion PRO
The training sessions consist of virtual reality based rehabilitation exercises using the MindMotion PRO device.
|
Device: MindMotion PRO
Patients will receive five weeks of therapy with 2 sessions (minimum) per week lasting for 45-60 minutes each minimum. The training sessions are based on the MindMotion PRO's virtual reality exercises. |
- Rehabilitation dose: goal-directed movements (i.e. number of intended movements to achieve a task) [ Time Frame: 5 weeks ]Rehabilitation dose: goal-directed movements (i.e. number of intended movements to achieve a task)
- Training intensity: number of goal-directed movements per minute of effective training time. [ Time Frame: 5 weeks ]Training intensity: number of goal-directed movements per minute of effective training time.
- Change in Upper limb function assessed with Fugl-Meyer Assessment for Upper Extremity (FMA-UE) [ Time Frame: At baseline, 5 weeks (post intervention) and 9 weeks (follow-up) ]Fugl-Meyer Assessment for Upper Extremity (FMA-UE)
- Change in Functional Independence Measure (FIM) [ Time Frame: At baseline, 5 weeks (post intervention) and 9 weeks (follow-up) ]
- Change in kinematic metrics/goniometry (active range of motion). [ Time Frame: At baseline, 5 weeks (post intervention) and 9 weeks (follow-up) ]
- Change in Modified Medical Research Council Scale (mMRCS) [ Time Frame: At baseline, 5 weeks (post intervention) and 9 weeks (follow-up) ]
- Change in Visual Analog Scale (VAS) for Pain [ Time Frame: At baseline, 5 weeks (post intervention) and 9 weeks (follow-up) ]
- Safety and Acceptance of Technology assessed with a questionnaire [ Time Frame: 5 weeks ]
Participants will answer a questionnaire to evaluate following aspects:
- Tolerance to VR intervention
- Adverse event monitoring
- Self-evaluation
- Acceptance of technology
- Motivation

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Ischemic or hemorrhagic minor-to-moderate (0<NIHSS<16) stroke with hemiparesis and experiencing arm motor difficulties
- At least 6 months after stroke incident
- Maximum 4 on the Medical Research Council Scale (MRCS) for shoulder elevation and elbow flexion/extension
- 18 years and older
- First ever stroke
Exclusion Criteria:
- Participating in another movement treatment study at the time of the present study
- Severe cognitive impairment (Mini Mental Status Examination score < 18 points)
- Orthopedic impairment or visual disorders limiting the treatment
- Unable to give informed consent form
- Risk of epileptic seizures

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03094650
Switzerland | |
Center for Neuroprosthetics-Valais (EPFL) at Clinique Romande de Réadaptation | |
Sion, Valais, Switzerland |
Responsible Party: | Mindmaze SA |
ClinicalTrials.gov Identifier: | NCT03094650 |
Other Study ID Numbers: |
MindMaze-2015-CT01 |
First Posted: | March 29, 2017 Key Record Dates |
Last Update Posted: | March 29, 2017 |
Last Verified: | March 2017 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
stroke neurorehabilitation virtual reality rehabilitation dose motor rehabilitation |
Stroke Motor Disorders Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases |
Nervous System Diseases Vascular Diseases Cardiovascular Diseases Mental Disorders |